Aurora Cannabis (ACB) Competitors $4.47 +0.17 (+3.95%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$4.46 0.00 (-0.11%) As of 07:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACB vs. ARDX, ZYME, LENZ, OCS, ORIC, PRAX, COGT, CMRX, CDMO, and AVXLShould you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include Ardelyx (ARDX), Zymeworks (ZYME), LENZ Therapeutics (LENZ), Oculis (OCS), Oric Pharmaceuticals (ORIC), Praxis Precision Medicines (PRAX), Cogent Biosciences (COGT), Chimerix (CMRX), Avid Bioservices (CDMO), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry. Aurora Cannabis vs. Its Competitors Ardelyx Zymeworks LENZ Therapeutics Oculis Oric Pharmaceuticals Praxis Precision Medicines Cogent Biosciences Chimerix Avid Bioservices Anavex Life Sciences Aurora Cannabis (NASDAQ:ACB) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership. Do institutionals & insiders hold more shares of ACB or ARDX? 47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by insiders. Comparatively, 4.8% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media refer more to ACB or ARDX? In the previous week, Ardelyx had 1 more articles in the media than Aurora Cannabis. MarketBeat recorded 6 mentions for Ardelyx and 5 mentions for Aurora Cannabis. Ardelyx's average media sentiment score of 0.61 beat Aurora Cannabis' score of 0.15 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Ardelyx 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, ACB or ARDX? Aurora Cannabis has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurora Cannabis$246.72M1.02$1.63M$0.1140.64Ardelyx$333.61M3.01-$39.14M-$0.22-19.05 Do analysts recommend ACB or ARDX? Ardelyx has a consensus target price of $10.89, suggesting a potential upside of 159.88%. Given Ardelyx's higher probable upside, analysts clearly believe Ardelyx is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67Ardelyx 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is ACB or ARDX more profitable? Aurora Cannabis has a net margin of 1.32% compared to Ardelyx's net margin of -14.86%. Aurora Cannabis' return on equity of 0.13% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Aurora Cannabis1.32% 0.13% 0.10% Ardelyx -14.86%-34.45%-13.81% Which has more volatility and risk, ACB or ARDX? Aurora Cannabis has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. SummaryAurora Cannabis beats Ardelyx on 9 of the 17 factors compared between the two stocks. Get Aurora Cannabis News Delivered to You Automatically Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACB vs. The Competition Export to ExcelMetricAurora CannabisMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$241.72M$10.49B$5.54B$8.87BDividend YieldN/A2.09%5.39%4.10%P/E Ratio40.6416.6626.2319.90Price / Sales1.0229.93413.23113.66Price / Cash7.0322.7836.1356.90Price / Book0.573.648.045.38Net Income$1.63M$233.36M$3.15B$248.50M7 Day Performance4.93%1.00%1.44%2.04%1 Month Performance-16.76%3.01%3.62%4.84%1 Year Performance-8.78%-11.64%34.68%20.23% Aurora Cannabis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACBAurora Cannabis0.2936 of 5 stars$4.47+4.0%N/A-1.1%$241.72M$246.72M40.641,130ARDXArdelyx4.3664 of 5 stars$3.63+2.0%$10.89+200.0%-20.6%$868.51M$333.61M-16.5090ZYMEZymeworks1.9669 of 5 stars$12.47-0.1%$21.00+68.4%+53.5%$867.63M$93.38M-8.31460LENZLENZ Therapeutics1.3529 of 5 stars$30.48+1.8%$46.60+52.9%+76.5%$858.01MN/A-17.22110OCSOculis2.1866 of 5 stars$19.65+1.9%$35.33+79.8%+63.8%$857.92M$780K-7.442ORICOric Pharmaceuticals4.235 of 5 stars$10.00+7.4%$19.17+91.7%+41.6%$852.20MN/A-5.3580PRAXPraxis Precision Medicines3.2703 of 5 stars$41.63-1.7%$109.90+164.0%+18.0%$848.00M$8.55M-3.88110News CoveragePositive NewsCOGTCogent Biosciences2.7428 of 5 stars$7.26+0.4%$14.57+100.7%-10.1%$826.62MN/A-3.9580Positive NewsAnalyst ForecastAnalyst RevisionCMRXChimerix0.6762 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.9274 of 5 stars$12.50+0.1%$12.25-2.0%+86.5%$799.18M$139.91M-5.23320News CoverageHigh Trading VolumeAVXLAnavex Life Sciences3.9142 of 5 stars$9.30+2.3%$44.00+373.1%+155.9%$793.94MN/A-16.9140News CoveragePositive News Related Companies and Tools Related Companies Ardelyx Competitors Zymeworks Competitors LENZ Therapeutics Competitors Oculis Competitors Oric Pharmaceuticals Competitors Praxis Precision Medicines Competitors Cogent Biosciences Competitors Chimerix Competitors Avid Bioservices Competitors Anavex Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACB) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurora Cannabis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurora Cannabis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.